OPEN END-TURBO-OPTIONSSCHEIN - NOVO NORDISK ADR B | Real-time BOERSE MUENCHEN 11:31:39 05/07/2024 am IST | ||
| 16.91 EUR | -0.06% |
|
| Current month | -3.04% | ||
| 1 month | +2.55% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 05/24/05 | 16.91 | -0.06% |
| 04/24/04 | 16.92 | +2.42% |
| 03/24/03 | 16.52 | -4.73% |
| 02/24/02 | 17.34 | -3.07% |
| 01/24/01 | 17.89 | +2.52% |
Real-time BOERSE MUENCHEN
Last update July 05, 2024 at 11:31 am IST
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | HSBC |
| WKN | TT94ED |
| ISIN | DE000TT94ED4 |
| Date issued | 12/11/2021 |
| Strike | 49.94 $ |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 2.5 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 18.39 € |
|---|---|
| Lowest since issue | 0.61 € |
| Spread | 0.14 € |
| Spread % | 0.83% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
970
DKK
Average target price
952.2
DKK
Spread / Average Target
-1.84%
- Stock Market
- Certificates
- Certificat
